Lytix Biopharma to present at the American Society of Clinical Oncology (ASCO) Annual Meeting
Oslo, Norway, April 28, 2022 – Lytix Biopharma AS (Lytix), a clinical-stage company with an in situ vaccination technology platform targeting cancer indications, today announces that its abstract has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago June 3-7, 2022. Title: LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma.Presenter: Morten Nielsen, MD | National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital,